AQR Capital Management
ABEO icon

AQR Capital Management’s Abeona Therapeutics ABEO Stock Holding History

AQR Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$460K Sell
102,645
-11,875
-10% -$59.4K ﹤0.01% 3169
2025
Q4 		$604K Buy
114,520
+80,908
+241% +$407K ﹤0.01% 2815
2025
Q3 		$177K Buy
+33,612
New +$213K ﹤0.01% 3282
2021
Q1 		– Sell
-7,082
Closed -$278K – 2178
2020
Q4 		$278K Buy
7,082
+2,580
+57% +$87.9K ﹤0.01% 1990
2020
Q3 		$115K Sell
4,502
-264
-6% -$16.6K ﹤0.01% 2122
2020
Q2 		$347K Buy
4,766
+1,136
+31% +$78.5K ﹤0.01% 1854
2020
Q1 		$191K Buy
+3,630
New +$242K ﹤0.01% 1883
2019
Q4 		– Sell
-1,479
Closed -$84K – 2112
2019
Q3 		$84K Buy
+1,479
New +$111K ﹤0.01% 2087
2018
Q4 		– Sell
-1,197
Closed -$383K – 2177
2018
Q3 		$383K Sell
1,197
-273
-19% -$96.8K ﹤0.01% 2033
2018
Q2 		$588K Sell
1,470
-184
-11% -$80.4K ﹤0.01% 1921
2018
Q1 		$594K Sell
1,654
-165
-9% -$61.3K ﹤0.01% 1857
2017
Q4 		$721K Buy
1,819
+59
+3% +$24.4K ﹤0.01% 1791
2017
Q3 		$750K Buy
+1,760
New +$473K ﹤0.01% 1773

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AQR Capital Management's ABEO Position: Q1 2026 in Review

AQR Capital Management reduced its Abeona Therapeutics (ABEO) stake by 10% in Q1 2026, selling an estimated $59.4K and leaving 102,645 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #3169.

AQR Capital Management first reported a position in ABEO in Q3 2017 and has held it in 13 quarters since. The position peaked at $750K in Q3 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • AQR Capital Management held 102,645 shares of Abeona Therapeutics worth $460K as of Q1 2026.
  • AQR Capital Management sold 11,875 Abeona Therapeutics shares in Q1 2026, an estimated $59.4K.
  • Abeona Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3169 holding.
  • AQR Capital Management first reported a position in Abeona Therapeutics in Q3 2017 and has held it in 13 quarters since.
  • AQR Capital Management's Abeona Therapeutics position peaked at $750K in Q3 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.